patients at risk. A larger blind study of pre-eclamptic cases is now in progress with another, centre to try to relate the levels to the severity of the condition and to the wellbeing of the fetus.
Introduction
Chloroquine-resistant falciparum malaria responds to few drugs and new drugs are needed. The antimalarial activity of a group of chlorinated lincomycin analogues was first demonstrated in mice infected with Plasmodium berghei (Lewis, 1968) and in monkeys infected with P. cynomolgi (Powers, 1969; Schmidt et al., 1970) . Chloroquine-resistant P. falciparum infections in owl monkeys were also cured by these compounds (Powers and Jacobs, 1972) . Both in animals and in man infected with malaria clindamycin acted slowly (Miller et al., 1974) . Three day courses of quinine and clindamycin given in combination or sequentially, however, proved effective against chloroquine-resistant falciparum malaria in volunteers (Miller et al., 1974) . We tested clindamycin alone and in combination with quinine in Thais naturally infected with chloroquineresistant falciparum malaria. 
Methods
The study was performed at the Trad Provincial Hospital in southeast Thailand. The research methods have been described elsewhere . We operated a daily malaria clinic at the hospital and suitable outpatients volunteered for the inpatient studies. Male patients with an asexual parasite count over 1 x 1091/ were included. Informed consent was obtained in all cases. To avoid the problem of immunity patients with clinically mild infections were rarely studied. Quantitative parasite counts were made at least twice daily in hospital on blood specimens obtained by finger-prick at 07.00 and 14.00 hours and at follow-up examinations on days 14, 21, and 28. Determination of the packed cell volume and leucocyte count was made on admission and whenever clinically indicated. Sera were collected on admission and the concentrations of bilirubin and creatinine determined.
Throughout the study the drugs were administered by one of the study physicians during medication ward rounds, usually at 06.00, 14.00, and 21.00 hours. The patients were observed by the physician as they swallowed the drug with water and then examined and kept under observation for a few minutes. The clindamycin was dispensed as 150-mg capsules, the usual dose being 450 mg every eight hours for three days (total dose 4050 mg). The quinine was administered as sugar-coated tablets of quinine sulphate (U.S.P.), each containing 270 mg base. The usual dose was 540 mg every eight hours for three days (total dose 4860 mg).
Follow Case 19.-This patient received four full doses of quinine (three intravenously) without toxicity. He then received quinine and clindamycin at half dosage. After two doses he developed nausea, tightness in the chest, and severe retching which persisted for eight hours. The clindamycin was stopped. The symptoms improved though the quinine therapy was continued. After the nine-dose course had been completed the clindamycin was resumed until nine doses had been given. The patient had persistent weakness during that time. The parasitaemia and fever cleared but follow-up until day 28 was not achieved.
Case 20.-This patient received five full doses of quinine at eighthour intervals uneventfully. Then the half-dose combination was given for two doses. The patient felt generally worse and a persistent fever developed. The clindamycin was stopped and also the quinine after two more doses. Sixteen hours later when he felt better the clindamycin was resumed for five doses, during which time he felt listless. A radical cure was achieved.
Case 22.-This patient was virtually asymptomatic on admission, having mild headache and backache only. After two doses of quinine 540 mg and clindamycin 300 mg at 10.00 and 21.00 hours on the day of admission, he developed nausea and vomiting, headache, dizziness, and prostration. Next day he received quinine 270 mg and clindamycin 150 mg at 06.00 and 14.00 hours. He remained severely toxic with weakness and dizziness though the parasite count had fallen from 60 to 0-65 x 10'/l. The clindamycin was stopped but the quinine was continued and the dose increased to 540 mg; he improved and remained well. After 12 doses of quinine a single dose of Fansidar was given. The patient was cured.
QUININE ALONE
Three patients (cases 27-29) were treated with a three-day course of quinine alone. They developed recrudescences on days 14, 22, and 25 respectively (table I).
TETRACYCLINE ALONE
Four patients received tetracycline 250 mg every six hours for three days (table II) . Two patients had an RIII response and one an RII response. A slow clearance of the parasitaemia occurred in the fourth patient but follow-up was not achieved. 
Discussion
Falciparum malaria in Thailand is difficult to eradicate in many patients. In recent studies the cure rates with chloroquine (Hall et al., 1975 b) and pyrimethamine (Doberstyn et al., 1975) were nil. Our results indicate that clindamycin is partially effective against chloroquine-resistant falciparum malaria in patients with clinically moderate disease. In some men the clinical response was rapid but in others it was slow or ephemeral. Our cure rate of 50% with multi-dose clindamycin contrasts with the 85% cure rate we obtained with a single dose of pyrimethamine and sulfadoxine (Doberstyn et al., 1975) . The average parasite clearance time for clindamycin (88 hours) was significantly longer (P <0 05) than that for pyrimethamine and sulfadoxine (71 hours). Wagner et al. (1968) found that clindamycin has a half life of only 2-38 hours, and consequently frequent doses must be given, which is a disadvantage in the treatment of malaria. On the other hand, sulfadoxine has a half life of about 200 hours (Brooks et al., 1969) . In our test system clindamycin was clearly a more powerful antimalarial than tetracycline (table II) . Clindamycin alone was not toxic in our patients. Nevertheless, several workers have shown that lincomycin and clindamycin (a chlorinated lincomycin analogue) can cause ulcerative colitis and even pseudomembranous colitis (Cohen et al., 1973; Pittman et al., 1974; Tedesco et al., 1974) . The diarrhoea usually begins after four to nine days of therapy. Colitis was not detected in our patients. Clindamycin is probably the most potent antimalarial among the antibiotics. Because of its partial efficacy and potential toxicity, however, clindamycin alone has a limited role as an antimalarial.
Quinine and clindamycin in combination at full or half dosage apparently potentiated toxicity in our patients. Millerc et al. (1974) , however, did not encounter gastrointestinal intolerance. In our patients retching and frank vomiting were commonly observed, whereas other patients had less specific symptoms and did not look well. When the clindamycin was stopped but the quinine continued the patients improved. Likewise, when the course of quinine had been completed clindamycin alone did not cause serious side effects. The therapeutic results with full-dose quinine and clindamycin therapy were excellent, all four patients followed up being cured. Possibly quinine and clindamycin potentiate both antimalarial efficacy and toxicity. Sequential administration of quinine and clindamycin was not toxic and could be useful in patients who have relapsed after more conventional treatment-for example, quinine followed by Fansidar.
By studying high-count rather than low-count cases we produced a more severe test of antimalarial efficacy in any regimen studied-that is, the degree of "drug pressure" was increased. If only patients with counts over 50 x 109/1 and uncomplicated disease are selected for drug trials comparative studies may be completed using fewer subjects. We have adopted this system without risk to the patients.
